ASX Share rice
Tue 11 May 2021 - 05:49:pm (Sydney)

PTX Share Price

PRESCIENT THERAPEUTICS LIMITEDPTXPharmaceuticals, Biotechnology & Life Sciences

PTX Company Information

Name:

Prescient Therapeutics Limited

Sector:

Healthcare

Industry:

Biotechnology

GIC Industry:

Biotechnology

GIC Sub Industry:

Biotechnology

Address:

100 Albert Road Melbourne VIC Australia 3205

Phone:

61 3 9692 7222

MD, CEO & Director:

Mr. Yatomi-Clarke Steven Lee

CFO & Company Sec.:

Ms. Melanie Jaye Leydin C.A., B.Bus, CA

Chief Scientific Officer:

Prof. Said M. Sebti Ph.D., M.D.

Chief Medical Officer:

Dr. Terrence G. Chew

Head of Bus. Devel.:

Dr. James D. Winkler

Company Overview:

Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of a range of cancers in Australia. The company's lead drug candidate is PTX-200, which is in Phase II clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. Prescient Therapeutics Limited has a collaboration agreement with Carina Biotech to develop cell therapies. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in South Melbourne, Australia.

PTX Share Price Information

Shares Issued:

640.55M

Market Capitalisation:

$57.65M

Revenue (TTM):

$1.08M

Revenue Per Share (TTM):

$0

Earnings per Share:

$-0.016

Operating Margin (TTM):

$-3.28

Return On Assets (TTM):

$-0.12

Return On Equity (TTM):

$-0.20

Quarterly Revenue Growth (YOY):

-0.002

Gross Profit(TTM):

$1.08M

Diluted Earnings Per Share (TTM):

$-0.007

PTX CashFlow Statement

CashFlow Date:

2020-06-30

Change To Liabilities:

$267.21K

Net Income:

$-3,321,189

Total Cash From Operating Activities:

$-2,317,182

Depreciation:

$0.90K

Change To Account Receivables:

$87.36K

Capital Expenditures:

$0

PTX Income Statement

Income Date:

2020-06-30

Income Before Tax:

$-3,321,190

Net Income:

$-3,321,190

Operating Income:

$-3,344,570

Interest Expense:

$4.19K

Total Revenue:

$70.36K

PTX Balance Sheet

Balance Sheet Date:

2020-06-30

Intangible Assets:

$3.37M

Total Liabilities:

$883.95K

Total Stockholder Equity:

$11.19M

Other Current Liabilities:

$182.37K

Total Assets:

$12.07M

Common Stock:

$63.93M

Other Current Assets:

$1.03M

Retained Earnings:

$-53,458,095

Other Liabilities:

$19.71K

Cash:

$7.36M

Total Current Liabilities:

$864.24K

Short-Term Debt:

$156.88K

Property - Plant & Equipment:

$38

Net Tangible Assets:

$7.82M

Total Current Assets:

$8.71M

Net Receivables:

$1.06M

Short-Term Investments:

$3.37M

Accounts Payable:

$479.92K

Short-Term Investments:

$3.37

Non Current Liabilities Total:

$19.71K

PTX Share Price History

PTX News

25 Feb, 2021
We can readily understand why investors are attracted to unprofitable companies. For example, Prescient Therapeutics...
10 Nov, 2020
This article will reflect on the compensation paid to Yatomi-Clarke Lee who has served as CEO of Prescient...